
1. Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020
May 4.

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in
Renal Cell Carcinoma Patients.

Derosa L(1), Routy B(2), Fidelle M(3), Iebba V(4), Alla L(5), Pasolli E(6),
Segata N(7), Desnoyer A(8), Pietrantonio F(9), Ferrere G(4), Fahrner JE(10), Le
Chatellier E(5), Pons N(5), Galleron N(5), Roume H(5), Duong CPM(4), Mondragón
L(11), Iribarren K(12), Bonvalet M(4), Terrisse S(13), Rauber C(14), Goubet
AG(14), Daillère R(12), Lemaitre F(12), Reni A(4), Casu B(4), Alou MT(4), Alves
Costa Silva C(4), Raoult D(15), Fizazi K(16), Escudier B(16), Kroemer G(17),
Albiges L(18), Zitvogel L(19).

Author information: 
(1)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France;
Department of Medical Oncology, Gustave Roussy Cancer Campus (GRCC), Villejuif,
France. Electronic address: deros.lisa@gmail.com.
(2)Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de
l'Université de Montréal (CHUM), Montréal, QC, Canada; Centre de Recherche du
Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal l, Canada CHUM,
Montréal, QC, Canada.
(3)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France; Center of
Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif,
France; Faculté de Pharmacie, University Paris-Saclay, Chatenay-Malabry, France.
(4)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France.
(5)Université Paris-Saclay, INRAE MetaGenoPolis, Jouy-en-Josas, France.
(6)Department of Agricultural Sciences, University of Naples Federico II, Napoli,
Italy.
(7)Department CIBIO, University of Trento, Trento, Italy; Istituto Europeo di
Oncologie, Milan, Italy.
(8)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Faculté de Pharmacie, 
University Paris-Saclay, Chatenay-Malabry, France; Gustave Roussy Cancer Campus, 
Laboratory of Immunomonitoring in Oncology, CNRS-UMS 3655 and INSERM-US23,
Villejuif, France.
(9)IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy.
(10)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de 
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France; Transgene
S.A., Illkirch-Graffenstaden, France.
(11)Faculté de Médecine Kremlin-Bicêtre, Université Paris Sud, Université Paris
Saclay, France; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer
Campus, Villejuif, France; Equipe labellisée par la Ligue contre le cancer,
Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des
Cordeliers, Paris, France.
(12)EverImmune, GRCC, Villejuif, France.
(13)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de 
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France;
Department of Medical Oncology, Gustave Roussy Cancer Campus (GRCC), Villejuif,
France.
(14)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de 
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France.
(15)Aix-Marseille Université, MEPHI, IRD, IHU Méditerranée Infection, Marseille, 
France.
(16)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medical
Oncology, Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
(17)Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus,
Villejuif, France; Equipe labellisée par la Ligue contre le cancer, Université de
Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers,
Paris, France; EverImmune, GRCC, Villejuif, France; Aix-Marseille Université,
MEPHI, IRD, IHU Méditerranée Infection, Marseille, France; Pôle de Biologie,
Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for
Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department 
of Women's and Children's Health, Karolinska Institute, Karolinska University
Hospital, Stockholm, Sweden.
(18)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France;
Department of Medical Oncology, Gustave Roussy Cancer Campus (GRCC), Villejuif,
France.
(19)Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de 
la Santé et de la Recherche Médicale (INSERM) U1015, Équipe Labellisée-Ligue
Nationale contre le Cancer, Villejuif, France; Faculté de Médecine
Kremlin-Bicêtre, Université Paris Sud, Université Paris Saclay, France;
Department of Medical Oncology, Gustave Roussy Cancer Campus (GRCC), Villejuif,
France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
Villejuif, France; EverImmune, GRCC, Villejuif, France; Suzhou Institute for
Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. Electronic 
address: laurence.zitvogel@gustaveroussy.fr.

BACKGROUND: The development of immune checkpoint blockade (ICB) has
revolutionized the clinical outcome of renal cell carcinoma (RCC). Nevertheless, 
improvement of durability and prediction of responses remain unmet medical needs.
While it has been recognized that antibiotics (ATBs) decrease the clinical
activity of ICB across various malignancies, little is known about the direct
impact of distinct intestinal nonpathogenic bacteria (commensals) on therapeutic 
outcomes of ICB in RCC.
OBJECTIVE: To evaluate the predictive value of stool bacteria composition for ICB
efficacy in a cohort of advanced RCC patients.
DESIGN, SETTING, AND PARTICIPANTS: We prospectively collected fecal samples from 
69 advanced RCC patients treated with nivolumab and enrolled in the GETUG-AFU 26 
NIVOREN microbiota translational substudy phase 2 trial (NCT03013335) at Gustave 
Roussy. We recorded patient characteristics including ATB use, prior systemic
therapies, and response criteria. We analyzed 2994 samples of feces from healthy 
volunteers (HVs). In parallel, preclinical studies performed in RCC-bearing mice 
that received fecal transplant (FMT) from RCC patients resistant to ICB (NR-FMT) 
allowed us to draw a cause-effect relationship between gut bacteria composition
and clinical outcomes for ICB. The influence of tyrosine kinase inhibitors (TKIs)
taken before starting nivolumab on the microbiota composition has also been
assessed.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metagenomic data (MG) from whole
genome sequencing (WGS) were analyzed by multivariate and pairwise
comparisons/fold ratio to identify bacterial fingerprints related to ATB or prior
TKI exposure and patients' therapeutic response (overall response and
progression-free survival), and compared with the data from cancer-free donors.
RESULTS AND LIMITATIONS: Recent ATB use (n = 11; 16%) reduced objective response 
rates (from 28% to 9%, p < 0.03) and markedly affected the composition of the
microbiota, facilitating the dominance of distinct species such as Clostridium
hathewayi, which were also preferentially over-represented in stools from RCC
patients compared with HVs. Importantly, TKIs taken prior to nivolumab had
implications in shifting the microbiota composition. To establish a cause-effect 
relationship between gut bacteria composition and ICB efficacy, NR-FMT mice were 
successfully compensated with either FMT from responding RCC patients or
beneficial commensals identified by WGS-MG (Akkermansia muciniphila and
Bacteroides salyersiae).
CONCLUSIONS: The composition of the microbiota is influenced by TKIs and ATBs,
and impacts the success of immunotherapy. Future studies will help sharpen the
role of these specific bacteria and their potential as new biomarkers.
PATIENT SUMMARY: We used quantitative shotgun DNA sequencing of fecal microbes as
well as preclinical models of fecal or bacterial transfer to study the
association between stool composition and (pre)clinical outcome to immune
checkpoint blockade. Novel insights into the pathophysiological relevance of
intestinal dysbiosis in the prognosis of kidney cancer may lead to innovative
therapeutic solutions, such as supplementation with probiotics to prevent primary
resistance to therapy.

Copyright © 2020. Published by Elsevier B.V.

DOI: 10.1016/j.eururo.2020.04.044 
PMID: 32376136 

